- Details
- Category: Medical sciences and health
Vaginal Discharge: What You Need to Know**
**Vaginitis**: This is a common diagnosis in women's healthcare, and it often leads to symptoms like increased vaginal discharge, itching, burning, pain while urinating, and sometimes an unusual odor. It's important to note that some vaginal discharge changes naturally with a woman's menstrual cycle. If a doctor suspects an infection, they may test for Chlamydia and Neisseria gonorrhoeae, two common culprits. In postmenopausal women, discomfort, dryness, and even light bleeding can be caused by atrophic vaginitis, which is linked to hormonal changes. Certain medications like isotretinoin and some contraceptives can also lead to dryness and itching. Overdoing personal hygiene with soap and using highly absorbent panty liners can irritate the area. If someone has tried self-treatment with antifungal agents and their symptoms persist, it's crucial to seek a clinical examination.
**Diagnosis**: Doctors typically use office microscopy to diagnose vaginitis. If a large number of white blood cells are present, it's unusual and might suggest trichomoniasis, a sexually transmitted infection. If trichomonads aren't found, the doctor may consider testing for gonorrhea or chlamydial infection. There's also an over-the-counter diagnostic kit called Fem V, which can help. A positive result suggests bacterial vaginosis or trichomoniasis, while a negative result is likely a yeast infection.
**Bacterial Vaginosis: More Than Just Discharge**
**Bacterial Vaginosis (BV)**: BV occurs when there's a change in the usual balance of bacteria in the vagina, with an overgrowth of certain types. It's the most common cause of vaginal discharge and often comes with a foul odor. Surprisingly, more than half of women with BV don't experience any symptoms. However, BV is associated with some serious issues like postoperative infections, pelvic inflammatory disease, premature delivery (in specific cases), and an increased risk of HIV transmission.
**Risk Factors**: Certain behaviors or conditions can increase your risk of getting BV, including smoking, using intrauterine contraception, having a new male sexual partner, engaging in sex with another woman, or using products like perfumed soaps or douches.
**Diagnosis and Treatment**: BV can usually be diagnosed through a combination of medical history and laboratory tests. While patients might notice a distinctive "musty cheese" odor, the absence of an obvious smell doesn't rule out BV. Laboratory tests, such as Gram staining or the Amsel criteria, help doctors confirm the diagnosis.
**Treatment Options**: Fortunately, BV is treatable. Medications like clindamycin and metronidazole are commonly used, and they are effective. Metronidazole can be taken orally, while clindamycin is available as a vaginal cream. There are also lactobacilli gelatin tablets for the vagina that work well. Although less common, tinidazole is another option. Some treatments are FDA-approved, but it's essential to follow your doctor's advice on what's best for you. Avoid hydrogen peroxide douching and triple-sulfonamide cream, as they aren't effective.
**Recurrent BV**: If BV keeps coming back, it can be a challenge. Doctors will want to confirm the diagnosis, identify risk factors, and explore other potential causes. Treatment might involve using metronidazole gel regularly, but this can increase the risk of vaginal candidiasis (yeast infection). If all else fails, your doctor may suggest a more extended period of treatment with metronidazole gel. Treating sexual partners isn't typically effective in preventing recurrence. Some individuals find relief from recurrent BV by using vaginal suppositories or consuming yogurt with Lactobacillus bacteria.
Candidal Vaginitis: It’s More Common Than You Think
Vulvovaginal Candidiasis (VVC): After bacterial vaginosis, VVC is the next most common cause of vaginal discomfort, affecting 70% to 75% of women at some point in their lives. Candida albicans is the primary culprit in 80% to 90% of cases. Risk factors for VVC include conditions like type 1 diabetes, recent antibiotic use, condom and diaphragm use, spermicides, oral contraceptive use, pregnancy, hormone replacement therapy, and immunosuppression. Interestingly, self-diagnosis by patients is often wrong, being unreliable 50% of the time. Even when a swab detects Candida, asymptomatic treatment is not advised. Since VVC isn’t sexually transmitted, it’s unnecessary for partners to undergo treatment. Recurrent VVC, defined as four or more symptomatic episodes in a year, can lead to complications like vulvar vestibulitis and chorioamnionitis, although these are rare.
Symptoms and Diagnosis: The most common complaint with VVC is a burning or itching sensation. A thick, curd-like discharge, inflammation, and lack of odor are usually indicative of VVC. However, in some cases, a thin discharge may be present despite the presence of VVC.
Diagnosis Methods: Office microscopy is often the first step in diagnosing VVC, but the gold standard is a culture. Vaginal pH is usually below 5.0 with C. albicans but can be higher with other non-albicans species. To rule out other conditions like trichomoniasis or bacterial vaginosis, a wet mount is performed. A potassium hydroxide (KOH) examination is also carried out but has varying sensitivity. Therefore, if a patient with persistent or recurrent symptoms has negative wet mount and KOH results, a culture is recommended. Rapid antigen testing is a more sensitive alternative to a wet mount, but a negative result still necessitates a culture.
Effective Treatment: Imidazoles are the primary treatment for VVC. Over-the-counter (OTC) intravaginal imidazoles like clotrimazole, miconazole, and tioconazole come in 1-, 3-, and 7-day regimens and are as effective as oral therapies. Single-dose therapy can be just as effective as multiple doses. However, lactobacillus, whether administered vaginally or orally, doesn’t prevent post-antibiotic-associated vaginal candidiasis.
Recurrent VVC: Around 5% to 8% of women experience recurrent VVC. Treatment typically involves a longer course of medication, followed by suppressive therapy using a weekly fluconazole dose for six months. It’s uncertain whether oral or intravaginal regimens are superior. Unfortunately, other remedies like boric acid, tea tree oil, garlic, douching, or treating male sexual partners haven’t proven effective in preventing recurrence. Lactobacillus in the form of suppositories or oral yogurt also doesn’t appear to help.
Trichomoniasis: The Sneaky Protozoan
Trichomoniasis: This infection is caused by a motile protozoan and affects millions of women worldwide annually, often transmitted sexually. Risk factors for acquiring it include multiple sexual partners and possibly changes in vaginal acidity. Men are usually asymptomatic carriers, but 10% of nongonococcal urethritis cases in men are caused by Trichomonas.
Symptoms and Diagnosis: Up to 50% of women with trichomoniasis don’t show symptoms. When they do, symptoms may include a yellow-green, foul-smelling discharge, vaginal burning, and painful urination. Physical examination may reveal cervical lesions, though this is rare. More common signs are a malodorous purulent discharge, vaginal tenderness, vulvar redness, and swelling. Office microscopy is the primary diagnostic tool. However, culture is the gold standard, as microscopic examination may not detect motile trichomonads in all cases. There are FDA-approved point-of-care tests for trichomoniasis, but they can produce false-positive results.
Effective Treatment: Metronidazole or tinidazole in a single-dose therapy is effective. An alternative is metronidazole taken orally twice daily for a week. Metronidazole gel is less effective, with less than a 50% cure rate. Patients allergic to metronidazole may need desensitization. It’s crucial to avoid alcohol while using nitroimidazoles. Metronidazole is considered safe in the first trimester of pregnancy. Since many male sexual partners are asymptomatic carriers, simultaneous treatment is advisable.
When Treatment Fails: If initial treatment with a single 2-gram dose of metronidazole fails, a trial of metronidazole, 500 mg twice daily for 7 days, or a single 2-gram dose of tinidazole is recommended. If these fail as well, a trial of tinidazole or metronidazole, 2 grams orally once daily for 5 days, is advised. Referral to a specialist is necessary if treatment remains unsuccessful.
Other Forms of Vaginitis: Besides VVC and trichomoniasis, other forms of vaginitis exist.
• Aerobic Vaginitis: This is characterized by purulent vaginal discharge due to an abnormal aerobic flora. It causes a foul-smelling non-fishy discharge, and sometimes inflammation and ulcers. Clindamycin topical treatment is often effective.
• Irritant and Allergic Vaginitis: These conditions can arise from various sources, such as spermicidal products, douching solutions, diaphragms, latex condoms, and topical medications. The remedy is to stop using the irritant.
• Cytolytic Vaginitis: This occurs due to an overgrowth of lactobacilli and squamous epithelial cell exfoliation. While it can mimic VVC, treatment involves discontinuing intravaginal medications.
• Desquamative Inflammatory Vaginitis: This condition involves copious purulent discharge with epithelial cell exfoliation, often linked to lichen planus. Treatment options include corticosteroids or clindamycin suppositories.
Remember, if you're experiencing unusual symptoms or discomfort, it's always a good idea to consult with a healthcare professional for proper evaluation and guidance.
- Details
- Category: Medical sciences and health
**Unveiling the Mystery of Pelvic Masses**
When it comes to pelvic masses, the journey of diagnosis can begin in various ways. Sometimes a patient experiences symptoms linked to a pelvic mass, while in other cases, it's serendipitously stumbled upon during a routine pelvic exam or ultrasound for different concerns. These masses can take residence in the uterus, ovaries, or even non-gynecologic areas of the pelvis.
The first crucial step in this detective work is to delve into the patient's age, medical history, and risk factors. These details act as clues in the diagnostic puzzle. For instance, if we're dealing with a younger woman, an ovarian cyst might be a functional one—harmless. But in postmenopausal women, it's essential to consider the possibility of ovarian cancer. We're also interested in menopausal status, menstrual history, family medical history, the risk of sexually transmitted infections (STIs), signs of excess androgens (hormones like testosterone), and painful menstruation, known as dysmenorrhea.
Pelvic examinations, although not foolproof, can offer valuable insights into the diagnosis. However, they become less reliable as body mass index (BMI) increases. Nonetheless, they provide additional information such as the mass's location, its mobility, tenderness when the cervix is moved, pelvic tenderness, and any unusual vaginal discharge.
The next logical step in our investigation involves pelvic ultrasonography. Depending on the mass's size and location, this can be done either transabdominally or transvaginally. It's also essential to rule out pregnancy in premenopausal women. For postmenopausal women with adnexal masses (masses near the ovaries), we utilize Doppler ultrasonography, evaluate cyst appearance, and perform CA-125 testing to assess the risk of ovarian cancer.
Let's pause here to address some jargon:
- **Adnexal mass**: A mass located near the uterus and ovaries.
- **CA-125**: A blood test that measures a protein often elevated in ovarian cancer.
- **Doppler ultrasonography**: A special ultrasound technique to assess blood flow in the mass.
- **Transabdominal**: An ultrasound where the probe is moved across the abdomen.
- **Transvaginal**: An ultrasound where a probe is placed into the vagina for a closer look.
Now, let's explore specific types of pelvic masses:
**Uterine Fibroids:** These pesky growths can be found in about one-third of women of reproductive age. While some don't cause trouble, others lead to pelvic pain, pressure, and heavy or irregular bleeding. They even top the list of reasons for hysterectomies in the United States. Treatment options include watchful waiting, as fibroids often shrink after menopause. However, a hysterectomy, although definitive, involves major surgery with risks. Uterine-sparing procedures, such as myomectomy, are an option but may lead to symptom recurrence. Fibroids can also affect fertility, but their removal doesn't always improve it.
**Ovarian Cysts and Carcinoma:** Here, transvaginal ultrasonography comes to the rescue again. We find that simple cysts are usually benign, but complex cysts or those larger than 10 cm carry a higher malignancy risk. Malignant cysts tend to display increased blood flow when examined with Doppler ultrasonography. So when should we raise the red flag and refer to a specialist? Well, premenopausal women should be referred if their CA-125 levels are high, they have ascites (abnormal fluid accumulation), signs of metastasis, or a close relative with breast or ovarian cancer. Postmenopausal women should also seek specialized care if they have elevated CA-125 levels, ascites, a fixed pelvic mass, signs of ascites, or a family history of breast or ovarian cancer among first-degree relatives.
In the realm of treatment, oral contraceptives (OCs) are not typically used for functional ovarian cysts, although they can reduce their occurrence. We're still navigating the best treatments for ovarian cysts, as medical options remain relatively uncharted territory.
So, the world of pelvic masses is indeed a complex one, filled with various challenges, risks, and treatment options. It's a realm where early detection and proper evaluation play a pivotal role in ensuring the best outcome for our patients.
This chart summarizes the possible causes of a pelvic mass based on different organs:
1. Uterus:
- Uterine fibroid: Symptoms include pelvic pressure and heavy vaginal bleeding.
- Intrauterine pregnancy: Recognized by a positive pregnancy test and absence of menstruation (amenorrhea).
2. Fallopian Tubes:
- Ectopic pregnancy: Indicated by a positive pregnancy test, adnexal (near the ovaries) pain, or tenderness, and hemodynamic instability.
- Tubo-ovarian abscess: Associated with STI risk, pelvic pain, cervical motion tenderness, vaginal discharge, and fever.
3. Ovaries:
- Simple cysts: More common in premenopausal women, causing sharp pelvic pain and pressure.
- Endometriomas: Typically linked to dysmenorrhea (painful menstruation).
- Dermoid cysts (teratomas): May cause pelvic pressure.
- Ovarian carcinoma: Typically found in postmenopausal women.
- Polycystic ovarian syndrome: Characterized by hyperandrogenism, irregular menstrual cycles, and multiple cysts on ultrasound.
- Germ cell tumors: Associated with pelvic pressure, chromosomal abnormalities, and common in younger women (teens and 20s).
4. Intestines:
- Appendicitis: Presents with anorexia, right lower quadrant pain or tenderness, elevated white blood cell count, and fever.
- Diverticulitis: Features left lower quadrant pain or tenderness, cramping, constipation, more common in older individuals, and fever.
5. Urinary Tract:
- Bladder tumor: Often identified by hematuria (blood in urine).
- Pelvic kidney: Typically asymptomatic.
- Details
- Category: Medical sciences and health
**Abnormal Vaginal Bleeding Explained**
Normal menstrual bleeding occurs every 21 to 35 days and follows a pattern with phases before and after ovulation. Abnormal vaginal bleeding is a common concern, affecting 10% to 30% of women of reproductive age, with substantial associated costs. The American College of Obstetricians and Gynecologists (ACOG) has introduced a classification system for this condition known as PALM COEIN (Polyp, Adenomyosis, Leiomyoma, Malignancy and Hyperplasia, Coagulopathy, Ovulatory Dysfunction, Endometrial, Iatrogenic, Not yet classified).
**Adolescents:**
- Common abnormal bleeding presentations in adolescents include anovulation, menorrhagia (heavy bleeding), and amenorrhea.
- Anovulation can occur for up to 18 months post-menarche due to the maturing hypothalamic-pituitary axis.
- Menorrhagia in adolescents can sometimes indicate a bleeding disorder, with up to 24% affected.
- Evaluation includes blood tests, coagulation profile, and von Willebrand disease screening if necessary. Treatment often involves hormonal contraception.
**Reproductive-Age Women:**
- Causes of abnormal bleeding in reproductive-age women include pregnancy complications, anovulatory disorders, and pelvic issues.
- Ovulatory cycles are characterized by regularity, premenstrual syndrome symptoms, and cervical mucus changes.
- Anovulatory cycles are unpredictable, resulting in various bleeding patterns.
- Evaluation depends on bleeding type and may involve blood tests, imaging, and endometrial biopsy.
- Anovulation, often related to PCOS or hypothalamic issues, can lead to irregular and unpredictable bleeding.
- Treatment is necessary to reduce endometrial cancer risk, typically with progesterone-induced withdrawal bleeding.
**Acute Bleeding Episodes:**
- In acute bleeding episodes, women are likely anovulatory. Evaluation includes hemoglobin assessment, volume status, and biopsy in older women.
- Severe cases may require hospitalization and intervention.
**Amenorrhea:**
- Secondary amenorrhea (absence of menses for at least 6 months) causes may include pregnancy, hormonal imbalances, and medications.
- Evaluation involves history, physical exam, pregnancy test, and hormone level tests.
- Progesterone-induced withdrawal bleeding helps diagnose underlying causes.
**Perimenopausal Women:**
- Abnormal bleeding is common in the years leading to menopause.
- Most often due to anovulation caused by declining ovarian function.
- Structural issues (fibroids or polyps) or bleeding disorders can also contribute.
- Evaluation includes endometrial biopsy, especially in high-risk women.
**Postmenopausal Women:**
- Postmenopausal bleeding (after 12 months without menstruation) raises concerns of endometrial carcinoma.
- Around 10-20% of such bleeding is due to malignancy.
- Evaluation may involve pelvic ultrasound and endometrial biopsy to assess endometrial thickness.
- A thin endometrial stripe (less than 4 mm) usually excludes cancer.
In cases of cervical stenosis, surgical procedures may be necessary when ultrasound results are inconclusive.
- Details
- Category: Medical sciences and health
While the Pap smear remains a fundamental tool for cervical cancer screening, recent advancements in our understanding of HPV have transformed this field. HPV, the most prevalent sexually transmitted infection (STI), is most common among individuals aged 20 to 24, with a prevalence of 53.8% (Hariri et al., 2011). Surprisingly, 15% of women in this study who claimed to have never engaged in sexual activity tested positive for HPV. It's crucial for physicians to acknowledge that some participants may have hesitated to disclose their sexual activity, even in anonymous surveys. Additionally, some individuals may have had sexual contact they did not consider as intercourse. Risk factors for HPV infection encompass low socioeconomic status, the number of sexual partners in the past year, lifetime sexual partners, age at first intercourse, and marital status.
In terms of cervical cancer screening, level A recommendations from the Strength of Recommendation (SOR) taxonomy suggest initiating Pap test screening at the age of 21, with subsequent screenings every 3 years. An alternative screening approach for women aged 30 and older is the simultaneous performance of Pap smear and HPV testing, followed by co-testing every 5 years if both results are normal. These recommendations align with the epidemiology of HPV. Younger women are more susceptible to HPV infections, but most clear the infection without intervention. In contrast, older women are less likely to contract new HPV infections, with persistent HPV being the primary concern for cervical cancer. It's important to note that women are not obligated to undergo a Pap smear before starting hormonal contraception. Physicians can utilize visits when a Pap test is unnecessary to educate female patients about STIs, reproductive health, and to implement other evidence-based screening recommendations (American College of Obstetricians and Gynecologists [ACOG], 2012a).
Management guidelines for abnormal Pap smear results have also been updated to align with our understanding of HPV epidemiology (Saslow et al., 2012). These guidelines provide recommendations for managing specific populations, including adolescents, pregnant women, and postmenopausal women. You can find these guidelines online at the American Society for Colposcopy and Cervical Pathology (ASCCP) website (http://www.asccp.org). Generally, women with low-grade squamous intraepithelial lesions (LSIL), atypical squamous cells of undetermined significance (ASCUS) with positive HPV test results, and high-grade SIL (HSIL) should undergo colposcopy for further evaluation.
A summary of the ASCCP guidelines is as follows:
1. Normal Pap Result:
• Routine screening at intervals recommended by guidelines (e.g., every 3-5 years, depending on age and co-testing with HPV).
2. Atypical Squamous Cells of Undetermined Significance (ASCUS):
• Follow-up with HPV testing if available. If HPV is positive, proceed with colposcopy.
• If HPV is negative or unavailable, repeat Pap testing in 12 months.
3. Low-Grade Squamous Intraepithelial Lesion (LSIL):
• Women under 25 years old: Repeat Pap testing at 12 months.
• Women 25 years and older: HPV testing. If HPV is positive, proceed with colposcopy.
• If HPV is negative or unavailable, repeat Pap testing in 12 months.
4. High-Grade Squamous Intraepithelial Lesion (HSIL):
• Immediate colposcopy and biopsy for further evaluation.
5. Atypical Glandular Cells (AGC):
• Colposcopy and endocervical curettage (ECC).
6. Squamous Cell Carcinoma (SCC):
• Immediate referral for colposcopy, biopsy, and additional diagnostic and treatment measures as necessary.
7. Adolescents:
• Management depends on age, cytology, and HPV status. Most adolescents with LSIL or ASCUS may be observed with repeat testing.
8. Pregnant Women:
• Colposcopy may be delayed until after pregnancy for most findings.
• Immediate evaluation for high-grade lesions in some cases.
9. Postmenopausal Women:
• Management depends on age, cytology, and HPV status.
• Colposcopy for persistent abnormalities or high-grade lesions.
Please note that these are general guidelines, and specific management decisions should be made in consultation with a healthcare provider, considering individual patient factors and circumstances. The ASCCP guidelines may be updated periodically, so it’s important to refer to their official website or consult with a healthcare professional for the most current recommendations.
- Details
- Category: Medical sciences and health
Common Antibiotics by Class
Antimicrobial Class: β-lactams (disrupt cell wall synthesis by inhibiting formation of peptidoglycan cross-links)
Selected Agents:
• Penicillins: penicillin V, penicillin G
• Aminopenicillins: ampicillin, amoxicillin, bacampicillin
• Antistaphylococcal penicillins: methicillin, nafcillin, oxacillin, dicloxacillin
• Extended-spectrum penicillins: ticarcillin, piperacillin
• β-lactam–β-lactamase inhibitor combinations: ampicillin–sulbactam; amoxicillin–clavulanate; ticarcillin–clavulanate; piperacillin–tazobactam
• Carbapenems: imipenem, ertapenem, meropenem, doripenem
• Monobactam: aztreonam
• Cephalosporins: cefazolin, cephalexin, cefuroxime, ceftriaxone, cefotaxime, ceftazidime, cefdinir, cefepime, ceftaroline, cefoxitin, cefotetan
Selected Comments:
• Note allergies to penicillin or β-lactam antibiotics, especially Type 1 allergies (anaphylaxis, urticaria, angioedema, or bronchospasm).
• Cross-reactivity is low, except for aztreonam.
• Carbapenems are broad-spectrum but not effective against MRSA, Stenotrophomonas maltophilia, Burkholderia cepacia, Legionella spp., and Corynebacterium jeikeium.
• Aztreonam is safe for those with β-lactam allergies.
• Cephalosporins lack enterococci coverage and can lead to C. difficile colitis.
Antimicrobial Class: Glycopeptides (disrupt cell wall synthesis, steric hindrance)
Selected Agents:
• Vancomycin, telavancin
Selected Comments:
• Vancomycin complications: “red man’s syndrome,” nephrotoxicity, thrombocytopenia.
• Monitor vancomycin trough serum levels.
• Telavancin is more active but has greater nephrotoxicity.
Antimicrobial Class: Lipopeptide (disrupts cell membrane, potassium efflux)
Selected Agents:
• Daptomycin
Selected Comments:
• Inactivated by pulmonary surfactant; not effective for pneumonia.
• Risk of rhabdomyolysis; monitor CPK levels.
• Eosinophilic pneumonia can occur.
Antimicrobial Class: Oxazolidinones (disrupt protein synthesis at 50S ribosomal subunit)
Selected Agents:
• Linezolid, tedizolid
Selected Comments:
• Prolonged use can cause myelosuppression.
• Avoid with serotonergic agents.
• Effective for MRSA pneumonia.
Antimicrobial Class: Glycylglycine (disrupt protein synthesis at 30S ribosomal subunit)
Selected Agents:
• Tigecycline
Selected Comments:
• Prominent nausea and vomiting.
• Approved for specific infections; caution for non-approved use.
Antimicrobial Class: Folate Antagonist (inhibit nucleic acid synthesis)
Selected Agents:
• Trimethoprim–sulfamethoxazole (TMP-SMX)
Selected Comments:
• Active against many bacteria.
• Sulfa component has risks.
• Side effects include nephrotoxicity, hyperkalemia, and photosensitivity.
Antimicrobial Class: Fluoroquinolones (inhibit various enzymes and DNA gyrase)
Selected Agents:
• Ciprofloxacin, levofloxacin, gemifloxacin, moxifloxacin, norfloxacin, ofloxacin
Selected Comments:
• Can cause QTc prolongation.
• Risk of tendonitis; avoid in pregnancy and children.
Antimicrobial Class: Nitroimidazole (disrupt DNA and inhibit nucleic acid synthesis)
Selected Agents:
• Metronidazole
Selected Comments:
• Active against anaerobic bacteria.
• High doses cause nausea, vomiting, and neurotoxicity.
Antimicrobial Class: Tetracyclines (inhibit protein synthesis at 30S ribosomal subunit)
Selected Agents:
• Tetracycline, doxycycline, minocycline
Selected Comments:
• Avoid in pregnancy and children.
• Photosensitivity and other side effects.
Antimicrobial Class: Macrolides (inhibit protein synthesis at 50S ribosomal subunit)
Selected Agents:
• Azithromycin, clarithromycin, erythromycin, fidaxomicin
Selected Comments:
• Can cause QTc prolongation.
• Drug interactions and side effects vary.
Antimicrobial Class: Lincosamide (inhibits protein synthesis at 50S ribosomal subunit)
Selected Agents:
• Clindamycin
Selected Comments:
• Associated with C. difficile colitis.
• Active against many bacteria.
Antimicrobial Class: Rifamycins (inhibit RNA synthesis)
Selected Agents:
• Rifampin, rifapentine, rifabutin, rifamixin
Selected Comments:
• Use in combination.
• Risk of hepatitis and allergic reactions.
Antimicrobial Class: Aminoglycosides
Selected Agents:
• Streptomycin, gentamicin, tobramycin, amikacin
Selected Comments:
• Nephrotoxicity, auditory, and vestibular toxicity.
• Use with caution.
Antimicrobial Class: Polymyxins
Selected Agents:
• Polymyxin B, colistimethate
Selected Comments:
• Expanding use for resistant bacteria.
• Risk of nephrotoxicity and neuromuscular blockade.
Antimicrobial Class: Nitrofuran (inhibits protein, DNA, RNA, and cell wall synthesis)
Selected Agents:
• Nitrofurantoin
Selected Comments:
• Acute and chronic pulmonary reactions.
• Common side effects.
Antimicrobial Class: Streptogramins (inhibit protein synthesis at 50S ribosomal subunit)
Selected Agents:
• Quinupristin–dalfopristin
Selected Comments:
• Synergistic against gram-positive bacteria.
• Indicated for specific infections.
Antimicrobial Class: Phosphonic Acid Derivative (blocks cell wall synthesis)
Selected Agents:
• Fosfomycin
Selected Comments:
• Broadly active against gram-negative and gram-positive bacteria.
• Used for UTIs as a single megadose.
I hope this helps make the information more accessible!
- Details
- Category: Medical sciences and health
Introduction - **Understanding Lung Cancer: A Complex Disease**
Lung cancer is a diverse group of malignant conditions, primarily categorized into small cell lung cancer (SCLC) comprising 13% of cases, and nonsmall cell lung cancer (NSCLC) making up 86% of cases. Additionally, there are rare thoracic malignancies like mesothelioma and lower-grade neuroendocrine tumors that fall under this umbrella.
In 2016, the American Cancer Society estimated that 224,390 individuals in the United States would be diagnosed with lung cancer, and tragically, 158,080 would succumb to this disease. It's important to note that lung cancer is not a single entity but rather a collection of distinct cancers, each with its unique characteristics.
Historically, lung cancer has posed a significant health challenge. In the case of men, the age-adjusted death rate for lung cancer hit its peak in 1990 at approximately 90 deaths per 100,000 individuals and has since declined to 60 per 100,000. In contrast, for women, the incidence reached a plateau around 1998, stabilizing at 53 per 100,000. These shifts can be attributed, in part, to changing smoking patterns.
Although there has been a decrease in smoking rates in developed countries, lung cancer persists as the leading cause of cancer-related fatalities in both men and women in the United States. This sobering fact also holds true globally, where lung cancer ranks as the top cause of cancer-related death. It underscores the critical need for ongoing research, early detection, and innovative treatment approaches in the battle against lung cancer.
**Lung Cancer and Non-Smokers: A Unique Perspective**
Lung cancer isn't exclusively linked to smoking; it can also be associated with other factors such as exposure to wood smoke, past chest radiotherapy, and certain metals like arsenic, chromium, nickel, beryllium, and cadmium. Nevertheless, it's essential to recognize that the contribution of these factors to the overall occurrence of lung cancer is relatively minor.
Now, let's delve into a specific group: individuals who have never smoked. Surprisingly, an estimated 25,000 deaths occur annually in the United States due to lung cancer among non-smokers. If considered separately, this would rank as the seventh leading cause of cancer-related deaths. Remarkably, 10% to 20% of all lung cancers are not linked to tobacco or other environmental exposures.
Interestingly, it's uncertain whether the incidence of lung cancer in never-smokers is on the rise or if it has always existed at a level that was previously undetected. In the early 1900s, before smoking became widespread, lung cancer diagnoses might have been overlooked or even confused with tuberculosis. Additionally, some populations seem more susceptible to developing lung cancer without smoking, such as women more than men, and African Americans and Asians more than Caucasians. Researchers have identified potential genetic factors that may make certain individuals more prone to this form of lung cancer.
While risk factors for lung cancer in never-smokers include exposure to secondhand smoke, radon, air pollution, occupational hazards, and genetic predisposition, the majority of patients in this category have no identifiable direct cause. What's intriguing is that the biology of lung cancer in non-smokers differs from that of smoking-related lung cancer. Adenocarcinoma, a subtype of nonsmall cell lung cancer (NSCLC), is the most common histological type among non-smokers. Notably, these tumors appear less complex than those in smokers and are more likely to possess specific genetic mutations that can be targeted with precision treatments (refer to "Molecular Changes in Nonsmall Cell Lung Cancer").
In summary, lung cancer is a multifaceted disease with various risk factors, and understanding its occurrence in non-smokers provides valuable insights into its complex nature. While smoking remains a predominant cause, it's evident that other factors, including genetics, play significant roles in shaping the landscape of lung cancer.
**Clinical Indicators and Paraneoplastic Syndromes in Lung Cancer**
*Clinical Detection of Lung Cancer Symptoms:*
In individuals who are heavy smokers, the symptoms of lung cancer often resemble the effects of chronic tobacco use. Many patients initially present with cough, worsening difficulty in breathing, or coughing up blood (hemoptysis), which can also be symptoms of conditions like bronchitis or pneumonia. However, symptoms such as significant weight loss, chest pain, bone pain, hoarseness, or neurological issues should trigger a more extensive medical evaluation as they often correspond to invasive or metastatic lung cancer.
*Paraneoplastic Syndromes:*
Paraneoplastic syndromes are more frequently observed in patients with Small Cell Lung Cancer (SCLC) but can occur in both types of lung cancer.
*Hematologic Abnormalities:*
Leukocytosis, an elevated white blood cell count, has been detected in up to 15% of Non-Small Cell Lung Cancer (NSCLC) patients, possibly due to the tumor's secretion of granulocyte colony-stimulating factor. In some cases, this condition leads to white blood cell counts over three times the upper limit of normal, referred to as a leukemoid reaction. Anemia is another common finding, affecting up to 40% of NSCLC patients, while thrombocytosis (elevated platelet count) is observed in up to 15% of cases.
*Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH):*
Around 10% of SCLC patients may secrete antidiuretic hormone, leading to severe hyponatremia (low sodium levels) even when fluid balance is normal (euvolemia). This syndrome responds to treating the underlying cancer, but in the meantime, it can be managed with measures like limiting water intake, certain medications like demeclocycline, and vasopressor receptor antagonists such as tolvaptan or conivaptan. It's crucial to avoid rapid sodium level correction as it can lead to a condition called central pontine myelinolysis.
*Hypercalcemia:*
Hypercalcemia, elevated calcium levels, can result from direct bone involvement by cancer or the secretion of factors that activate bone-resorbing cells (osteoclasts). High levels of parathyroid hormone-related peptide are often associated with NSCLC of squamous histology and can lead to clinical symptoms like excessive thirst, kidney stones, renal failure, nausea, constipation, and in severe cases, confusion or coma. Treatment typically includes intravenous (IV) hydration, bisphosphonates, and/or calcitonin.
*Cushing Syndrome:*
Excessive production of adrenocorticotropic hormone (ACTH) by tumor tissue can cause Cushing syndrome, characterized by symptoms like obesity concentrated around the trunk, hypertension, high blood sugar, low blood potassium levels (hypokalemic alkalosis), and osteoporosis. This is predominantly observed in patients with SCLC and is often a sign of a poor prognosis.
*Pancoast Syndrome:*
Lung tumors originating in the superior sulcus of either lung can damage the brachial plexus and sympathetic ganglia, leading to Pancoast syndrome. This syndrome is marked by shoulder and arm pain, a condition called Horner syndrome affecting one side of the face, bone destruction, and muscle atrophy in the hand. Typically, these tumors arise from NSCLC of squamous histology.
*Thrombosis:*
All cancer patients have an increased risk of developing blood clot-related disorders like deep vein thrombosis and pulmonary embolism. If spontaneous blood clots form without an apparent cause, it's essential to screen for an underlying malignancy. These patients should be treated with low-molecular-weight heparin instead of warfarin.
*Hypertrophic Pulmonary Osteoarthropathy:*
Associated primarily with NSCLC, hypertrophic pulmonary osteoarthropathy exhibits symptoms such as clubbing of the fingers, inflammation of the outer lining of long bones (periostitis), arthritis, and skin thickening. In addition to addressing the underlying malignancy, symptomatic treatment may involve nonsteroidal anti-inflammatory drugs and bisphosphonates.
*Lambert-Eaton Syndrome:*
Lambert-Eaton syndrome (LES) is an uncommon paraneoplastic syndrome, more often associated with SCLC but occasionally seen in NSCLC. It manifests as muscle weakness in the limbs, reduced reflexes, and autonomic changes. While it may resemble myasthenia gravis in presentation, a key differentiator is that muscle strength improves with repeated activity in LES.
**Diagnosis and Screening for Lung Cancer**
*Diagnosis:*
The diagnosis of lung cancer typically begins with the identification of a lung nodule on a chest X-ray (CXR) or a more detailed CT scan. A contrast-enhanced CT scan of the chest provides an overview of the extent of disease within the lung tissue, regional lymph nodes, and potential metastasis to other sites like the bones, liver, or adrenal glands. Positron emission tomography (PET) scans, alone or combined with CT scans (PET/CT), are used to further assess regional or metastatic disease. Except for very small Non-Small Cell Lung Cancers (NSCLC) less than 1 cm in diameter, most patients with lung cancer should also undergo brain imaging, typically a brain MRI. If an MRI is not feasible, a head CT scan with contrast can be performed.
Establishing the diagnosis of NSCLC requires obtaining tissue for histopathologic analysis. In general, physicians aim to make the initial diagnosis through the least invasive method that provides the highest pathologic stage. Thus, patients with a suspected metastasis should have that site biopsied for accurate staging. Patients with potential involvement of mediastinal lymph nodes may undergo diagnostic mediastinoscopy. CT-guided fine-needle biopsy of the lung is often used for diagnosis but carries a risk of complications like pneumothorax and severe pulmonary bleeding. Bronchoscopy, sometimes combined with endobronchial ultrasound, is particularly useful for proximal tumors and can provide information about the primary tumor and lymph node staging. While diagnosis can be made through fine-needle aspiration, advanced molecular testing often requires more substantial tissue samples in the form of non-decalcified core biopsies or surgical specimens.
*Screening:*
Due to the high mortality associated with advanced lung cancer, especially among smokers, several trials have attempted lung cancer screening. While radiologic imaging can detect malignant lung nodules, these tumors tend to be less aggressive than those detected through clinical symptoms.
Early randomized trials, involving over 30,000 patients, utilized combinations of CXR and sputum cytology for screening. However, these studies didn't directly compare screening with no screening. Instead, they examined adding sputum cytology to CXR or variations in screening frequency. The general findings showed increased detection of early-stage lung cancer but no difference in survival rates. For example, the Mayo Lung Project observed more lung cancer-related deaths in the screened group at 20-year follow-up.
These less promising results with CXR screening led to exploration of modern CT scanning techniques. Observational cohort studies showed that CT scans could identify more early-stage lung cancers compared to CXR. However, CT scans also produced more false-positive results, necessitating additional biopsies. These scans often detected very early-stage tumors with potentially better natural outcomes than clinically identified tumors.
In the National Lung Screening Trial, over 50,000 smokers, aged 55 to 74 years, without symptoms, were randomized to undergo annual CXR or low-dose CT screening for three years. The results showed a 20% relative reduction in lung cancer-specific mortality and a 6.7% relative reduction in all-cause mortality with CT screening compared to CXR. These findings have led to the adoption of low-dose CT screenings for lung cancer in some centers.
The US Preventive Services Task Force updated its guidelines in December 2013, recommending annual low-dose CT screening for lung cancer in adults aged 55 to 80 years with a smoking history of 30 pack-years who either currently smoke or quit within the past 15 years. Screening should be discontinued if a person has not smoked for 15 years or if they develop a health issue limiting life expectancy or the ability or willingness to undergo curative lung surgery.
——————————————
**This list categorizes different histologic subtypes of Non-Small Cell Lung Cancer (NSCLC) along with their variants. Here's an explanation of each subtype:
**I. Squamous cell carcinoma Variants:**
- **Papillary**: A variant characterized by papillary growth patterns.
- **Clear cell**: A variant with clear cell features.
- **Small cell**: A variant displaying small cell characteristics.
- **Basaloid**: A variant featuring basaloid growth patterns.
**II. Adenocarcinoma:**
- *Preinvasive lesions:*
- **Atypical adenomatous hyperplasia**: Early abnormal growth of glandular cells.
- **Adenocarcinoma in situ (formerly BAC - Bronchioloalveolar carcinoma)**: Noninvasive cancer confined to the air sacs.
- **Nonmucinous**: Without mucus production.
- **Mucinous**: Producing mucus.
- **Mixed mucinous/nonmucinous**: Combining mucus and non-mucus-producing elements.
- **Minimally invasive adenocarcinoma**: Slightly invasive cancer with lepidic predominant growth pattern.
- **Nonmucinous**: Without mucus production.
- **Mucinous**: Producing mucus.
- **Mixed mucinous/nonmucinous**: Combining mucus and non-mucus-producing elements.
- *Invasive adenocarcinoma:*
- **Lepidic predominant**: Formerly nonmucinous BAC pattern, now with more extensive invasion.
- **Acinar predominant**: Characterized by acinar growth patterns.
- **Papillary predominant**: Dominated by papillary growth.
- **Micropapillary predominant**: Predominantly micropapillary growth.
- **Solid predominant with mucin production**: Features solid growth with mucus production.
- **Variants of invasive adenocarcinoma**:
- **Invasive mucinous adenocarcinoma (formerly mucinous BAC)**: Mucin-producing invasive adenocarcinoma.
- **Colloid**: Tumor with gelatinous or mucinous content.
- **Fetal (low and high grade)**: Resembling fetal lung tissue.
- **Enteric**: Displaying characteristics similar to the intestines.
**III. Large cell carcinoma Variants:**
- **Large cell neuroendocrine carcinoma**: A variant with features of both large cell carcinoma and neuroendocrine tumors.
- **Combined large cell neuroendocrine carcinoma**: Combining large cell and neuroendocrine carcinoma elements.
- **Basaloid carcinoma**: Featuring basaloid growth patterns.
- **Lymphoepithelioma-like carcinoma**: Resembling lymphoepithelioma.
- **Clear cell carcinoma**: A variant with clear cell characteristics.
- **Large cell carcinoma with rhabdoid phenotype**: Characterized by rhabdoid cell features.
**IV. Adenosquamous carcinoma**: A tumor consisting of both adenocarcinoma and squamous cell carcinoma components.
**V. Carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements**: Tumors showing pleomorphic, sarcomatoid (resembling soft tissue tumors), or sarcomatous (having characteristics of a sarcoma) features.
**VI. Unclassified carcinoma (i.e., poorly differentiated)**: Tumors that cannot be classified into the specific subtypes mentioned above and are generally poorly differentiated.
—_——————
**Nonsmall Cell Lung Cancer (NSCLC): Pathology and Staging**
**Pathology Histology of NSCLC:**
- NSCLC accounts for approximately 86% of primary lung tumors.
- It encompasses various morphologic subtypes, mainly adenocarcinoma and squamous cell carcinoma.
- Historically, histologic subtypes didn't impact treatment decisions, but certain therapies now show efficacy in specific histologic subtypes.
**Molecular Changes in NSCLC:**
- Clinically evident NSCLC exhibits numerous genomic abnormalities, with a high mutation rate, often exceeding 10 somatic mutations per megabase of DNA.
- These include dominant driver oncogenes like EGFR, KRAS, ALK, ROS1, RET HER2, BRAF, and MET, which are crucial for tumor growth.
- EGFR mutations, for example, occur in 10-15% of US NSCLC and 40-50% in Asian countries, frequently in never-smokers, women, and Asians, often associated with adenocarcinoma histology.
- EGFR mutations result in constant activation of EGFR signaling, driving tumor growth and preventing apoptosis.
- Small-molecule tyrosine kinase inhibitors (TKIs) like gefitinib, erlotinib, and afatinib are highly effective against various EGFR mutations.
**Staging of NSCLC:**
- Lung cancer staging follows the American Joint Committee on Cancer, seventh edition, staging system.
- Staging aims to determine the extent of disease, crucial for treatment decisions.
- If metastatic disease is confirmed, curative treatment is usually not an option.
- Due to the prevalence of metastatic disease (25-30% of lung cancer cases), even small tumors require comprehensive workup.
- Workup typically includes chest CT with IV contrast (common for diagnosis), PET with CT localization, head MRI with contrast (or head CT if MRI isn't feasible), pulmonary function testing (for potential surgery), and laboratory workup to rule out other health issues.
- Surgical candidates often underwent mediastinoscopy in the past to check for mediastinal nodal involvement.
- PET and PET/CT scans now identify lymph node involvement and metastatic disease, reducing unnecessary surgeries.
- A PET/CT scan with no enlarged mediastinal lymph nodes and no PET activity in the mediastinum has a low false-negative rate (5%).
**Small Cell Lung Cancer (SCLC)**
**Pathology of Small Cell Lung Cancer:**
- SCLC is an aggressive neuroendocrine tumor originating in the lungs.
- Strongly linked to smoking, it differs from NSCLC by its small cell size and the presence of neuroendocrine markers like chromogranin A and synaptophysin.
- Lower-grade neuroendocrine tumors (carcinoid tumors) from the lungs exist but are managed differently due to their slower growth and resistance to typical treatments.
**Diagnosis and Staging of Small Cell Lung Cancer:**
- Staging involves chest, abdomen, pelvis CT scans, cranial imaging, and bone or PET scans.
- Two categories: limited stage (confined to a single radiation field) and extensive stage (wider spread, often with metastases).
- SCLC frequently comes with paraneoplastic syndromes like inappropriate antidiuretic hormone secretion and Cushing syndrome.
**Treatment of Limited-Stage Small Cell Lung Cancer:**
- Standard care: concurrent full-dose chemotherapy (cisplatin and etoposide) with radiotherapy, followed by chemotherapy alone.
- This approach yields an over 80% response rate and a median survival of 14-20 months.
- After 5 years, 15-20% of patients might still be disease-free.
- Surgery isn't effective, as localized tumors tend to recur post-resection.
- Prophylactic cranial irradiation follows chemotherapy and radiation, enhancing overall survival.
**Extensive-Stage Small Cell Lung Cancer:**
- Incurable, with a median survival of 9-11 months.
- Initially treated with platinum-based doublet chemotherapy, but the response rate is higher (70-80%).
- Responding patients benefit from prophylactic cranial irradiation.
- Second-line therapy is more effective if the disease-free interval after initial therapy is longer than 3 months (relapsed disease) and often involves single-agent chemotherapy.
- Targeted therapies are not proven effective, though anti-PD1 immunotherapies might offer some benefits.
- Supportive care is crucial for managing SCLC.
- Details
- Category: Medical sciences and health
Introduction
Breast cancer is the most frequently occurring cancer among women in the United States, excluding skin cancers like basal and squamous cell carcinomas. It ranks as the second leading cause of cancer-related deaths in women. In the year 2016, there were about 246,660 new cases of breast cancer, accounting for 29% of all newly diagnosed cancers in women. Tragically, it also resulted in 40,450 deaths, making up 14% of cancer-related deaths in the female population.
Around 1998, the incidence and mortality rates for breast cancer reached their highest levels, with 145 cases and 32 deaths per 100,000 women. However, thanks to advancements in screening techniques, preventive measures, and the modification of risk factors, there has been a modest decline in breast cancer incidence, dropping to approximately 123 cases per 100,000 women. Additionally, earlier detection and improved treatments have led to a decrease in breast cancer mortality, with rates now standing at 22 cases per 100,000 women.
It's worth noting that breast cancer is more commonly diagnosed in Caucasian women, with an incidence rate of 128 cases per 100,000 women, compared to African-American women, who have an incidence rate of 124 cases per 100,000 women. However, when it comes to breast cancer-related deaths, African-American women face a higher rate of 31 deaths per 100,000 women, compared to Caucasian women, who experience 22 deaths per 100,000
**Breast Cancer Risk Factors**
Several factors contribute to the risk of developing breast cancer. These include gender (with females being at higher risk), age, benign breast conditions, exposure to ionizing radiation, family history of breast cancer, mutations in inherited cancer-related genes, race/ethnicity, dietary choices, alcohol consumption, and estrogen exposure.
- **Age and Gender**: Among these factors, age and gender are the most significant. Breast cancer risk increases with age, with half of all breast cancer cases being diagnosed after the age of 61. While breast cancer can affect men, it's extremely rare, accounting for only 1% of breast cancer cases in the United States.
- **Radiation Exposure**: Exposure to therapeutic chest radiation at a young age, typically used to treat conditions like lymphoma, is linked to an elevated risk of breast cancer. This has led to the need for early and more intensive breast cancer screening for individuals who received such radiation.
- **Family History**: A family history of breast cancer is another risk factor, but it's a bit complex. A woman's risk of developing breast cancer increases if she has a first-degree relative (like a mother or sister) who had breast cancer. This risk is even higher if the relative was diagnosed at a younger age or if multiple first-degree relatives were affected. However, only 15% to 20% of women with breast cancer have a family history of the disease.
- **Inherited Gene Mutations**: About 5% to 10% of breast cancer cases are linked to inherited gene mutations. Genes like BRCA1, BRCA2, TP53 (associated with Li-Fraumeni syndrome), and others are examples. Women with BRCA1 or BRCA2 mutations, for instance, can have a much higher lifetime risk of breast cancer, often around 80%. These mutations also increase the risk of ovarian and other cancers.
- **Body Weight**: Weight plays a role in breast cancer risk. Being overweight or obese after menopause is associated with an increased risk, with a body mass index (BMI) of 28 kg/m^2 or higher being linked to about a 25% greater risk compared to those with lower BMIs. The exact mechanism is debated, but it may involve higher levels of estrogen in the body due to fat tissue converting androgens into estrogen.
- **Hormone Use**: Menopausal hormone therapy (MHT) containing estrogen and progesterone can increase breast cancer risk. Studies like the Women's Health Initiative found that prolonged use of these therapies can lead to a greater risk of breast cancer. The risk may persist even after discontinuation.
- **Alcohol Consumption**: Alcohol intake is a known risk factor for breast cancer. For every 10 grams of alcohol consumed daily (equivalent to a 4-ounce glass of wine), there's a 10% increase in breast cancer risk.
Understanding these risk factors can help individuals and healthcare providers make informed decisions regarding screening, prevention, and lifestyle choices to reduce the risk of breast cancer.
**Preventing Breast Cancer**
There are several factors that can help reduce the risk of developing breast cancer:
- **Minimizing Hormone Therapy**: If you're going through menopause and considering hormone therapy (MHT), try to use it for the shortest time necessary. Prolonged MHT use can increase breast cancer risk.
- **Maintaining a Healthy Weight**: Avoid gaining excess weight as an adult, especially after menopause. Being overweight can increase your risk of breast cancer.
- **Regular Physical Activity**: Engage in regular physical exercise. It can help lower your breast cancer risk.
- **Limiting Alcohol**: Try to limit alcohol consumption. Drinking too much alcohol is linked to an increased risk of breast cancer.
- **Early Motherhood and Breastfeeding**: Having your first child at a younger age and breastfeeding for at least 6 months can reduce the risk of breast cancer.
For individuals with BRCA1/2 gene mutations, taking proactive steps like prophylactic mastectomy (removing the breasts) and prophylactic oophorectomy (removing the ovaries) can significantly reduce the risk of breast cancer.
**Medications for Prevention**
- **Selective Estrogen Receptor Modulators (SERMs)**: Medications like tamoxifen and raloxifene, when taken for a specified period (usually 5 years), can reduce the risk of invasive breast cancer by 50%. However, they do not necessarily improve overall survival. Tamoxifen does have some side effects, including a slightly increased risk of uterine cancer and blood clot formation. Tamoxifen has been studied for both premenopausal and postmenopausal women, while raloxifene has been mainly evaluated in postmenopausal women.
- **Aromatase Inhibitors (AIs)**: Medications like exemestane and anastrozole are also effective in preventing breast cancer in postmenopausal women. However, they are associated with side effects such as an increased risk of osteoporosis. The choice between SERMs and AIs depends on various factors, including bone health.
It's important to note that while AIs are as effective as SERMs, only SERMs are currently approved by the US Food and Drug Administration (FDA) for primary breast cancer prevention.
**Breast Cancer Screening**
Regular screening is vital for detecting breast cancer early:
- **Mammography**: Getting a mammogram every one or two years can help detect early-stage breast cancers before symptoms appear. The effectiveness varies by age, with a significant benefit seen in women aged 50 to 69. Most facilities use digital mammography, and some offer tomosynthesis (3D mammography), although its superiority over standard digital mammograms is uncertain. Possible downsides of screening include discomfort, false-positive results, radiation exposure, and overdiagnosis (detecting cancers that may not cause harm).
- **When to Start and Stop**: Experts recommend discussing mammography starting around age 40 with personalized risk assessment. Routine screening typically begins at age 45 or 50, depending on guidelines. For women in their 40s, the benefits are somewhat lower due to a lower risk of breast cancer and a higher risk of false positives. Decisions on when to stop screening should be tailored to individual circumstances, with some groups recommending screening as long as a woman's life expectancy exceeds ten years.
- **Breast Self-Exams**: Routine breast self-examinations are no longer advised. Instead, women should be aware of any breast changes and discuss them with their healthcare provider.
- **Additional Tests**: Ultrasound may be used to follow up on abnormal clinical findings or mammograms. MRI is more sensitive than mammography but is not routinely used for screening. It may be considered for high-risk individuals, such as those with certain gene mutations or a history of therapeutic chest radiation during childhood.
Regular screening is essential for early detection, which can improve breast cancer outcomes. The right screening plan should be discussed with a healthcare provider, considering individual risk factors.
**Understanding Breast Cancer Staging and Treatment**
Breast tissue is composed of epithelial elements (like ducts) and stromal elements (such as fatty and fibrous tissues). Over 95% of breast cancers develop from epithelial cells, making them carcinomas. These breast carcinomas can be either in situ (confined within ducts or lobules) or invasive (spreading into surrounding breast tissue and possibly to other parts of the body). In situ carcinomas include ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS). Invasive breast cancers encompass various histologic types, with invasive ductal carcinoma (IDC) being the most common, accounting for about 75% of cases.
Several factors affect breast cancer prognosis and treatment decisions, including the cancer's grade, stage, hormone-receptor status, and HER2 status. Grade describes the microscopic features of the cancer and is categorized as well-differentiated (grade 1), moderately differentiated (grade 2), or poorly differentiated (grade 3). Stage is based on tumor size (T), extent of lymph node involvement (N), and presence of distant metastases (M). Stage 0 refers to noninvasive cancer (e.g., DCIS or LCIS), while invasive cancers are classified as stage I, II, or III, depending on their size and extent of spread. Stage IV indicates cancer that has spread to distant sites.
Inflammatory breast cancer (IBC) is an aggressive type, presenting with warm, thickened skin and a peau d'orange appearance over the breast. Unlike other breast cancers, IBC often lacks a palpable mass. It usually requires intensive treatment, including neoadjuvant chemotherapy, mastectomy, and postmastectomy radiation therapy.
**Stage 0 Breast Cancer (Carcinoma in Situ)**
DCIS is a noninvasive cancer confined within the breast ducts, and it has become more common with the increased use of mammography. It accounts for about a quarter of newly diagnosed breast cancers. Surgical treatment options for DCIS include lumpectomy (removing the tumor while preserving the breast) or mastectomy (removing the whole breast). Lumpectomy followed by radiation therapy is the standard, reducing the risk of local recurrence by 50%. While axillary lymph node biopsy is unnecessary for pure DCIS, hormone therapy, such as tamoxifen or aromatase inhibitors (AIs), may be recommended after surgery to reduce future breast cancer risk.
LCIS is a noninvasive cancer arising from breast lobules. It's usually discovered incidentally during unrelated biopsies. LCIS itself doesn't require treatment, but it signals an increased risk of developing invasive breast cancer in either breast. Management options include surveillance or preventive medications like SERMs or AIs. Bilateral mastectomy isn't typically recommended.
**Stages I, II, and III Breast Cancer (Nonmetastatic)**
The goal for invasive breast cancer confined to the breast and/or axillary lymph nodes is cure. Surgical removal, either mastectomy or lumpectomy, is the primary treatment. Lumpectomy followed by radiation therapy is advised to reduce the risk of local recurrence. Axillary lymph node biopsy helps determine the prognosis and guide treatment. A sentinel node biopsy is preferred, allowing for less extensive axillary surgery if the sentinel nodes are clear. Hypofractionated radiation therapy may be an option for some women, shortening treatment duration.
The choice between mastectomy and lumpectomy depends on individual factors. Breast reconstruction is possible following mastectomy. Sentinel node biopsy and its results help decide whether additional axillary lymph node surgery is needed. While complications following complete dissection are uncommon, some women may experience chronic lymphedema.
Understanding the stage and characteristics of breast cancer is crucial for determining the appropriate treatment plan, ensuring the best possible outcome for each patient.
**Navigating Systemic Therapy for Breast Cancer**
In many cases, localized breast cancer can be effectively treated with surgery and radiation therapy. However, some patients remain at risk of developing metastatic disease even after these treatments. The likelihood of recurrence depends on factors like the stage and biological characteristics of the cancer, including its grade, hormone receptor status, and HER2 status. Unfortunately, blood tests and scans can't reliably predict who will experience recurrence.
The aim of adjuvant therapy is to lower the risk of cancer recurrence. This involves using systemic medications to target microscopic cancer cells that surgery or radiation might have missed. Decisions regarding adjuvant therapy depend on the risk of recurrence and the specific cancer type. Generally, the higher the risk, the more significant the potential benefit of adjuvant therapy.
Risk factors for metastatic breast cancer include larger tumor size, higher tumor grade, presence of lymphovascular invasion, hormone receptor-negative disease, and axillary node involvement. Additionally, gene expression analyses like the OncotypeDX recurrence score can help estimate the risk of recurrence for early-stage hormone-positive, HER2-negative breast cancer. This score provides insights into the likelihood of distant recurrence and the potential benefits of adding adjuvant chemotherapy to hormone therapy.
The choice of adjuvant therapy also hinges on the biological characteristics of the cancer. Hormone receptor-positive breast cancers (those with estrogen or progesterone receptors) can respond well to hormonal therapy. This treatment typically lasts 5 to 10 years, starting after surgery and, if applicable, chemotherapy. Tamoxifen is common for premenopausal women, often combined with ovarian suppression. Postmenopausal women may receive an aromatase inhibitor (AI) or a combination of tamoxifen and an AI. Adjuvant hormonal therapy can reduce the risk of death by about a third. Each therapy has its side effects: tamoxifen can increase the risk of thromboembolic disease and uterine cancer, while AIs may lead to musculoskeletal symptoms and osteoporosis.
Around 25% of breast cancers overexpress the HER2 protein. Patients with untreated HER2-positive breast cancer face a higher risk of recurrence. Trastuzumab, a monoclonal antibody, is used alongside adjuvant chemotherapy to target HER2-positive cancer cells. This combination significantly reduces the risk of recurrence and death. Trastuzumab may not be suitable for patients with preexisting heart failure, as about 2% to 3% of patients who receive it develop congestive heart failure. Monitoring the patient's heart function during treatment is recommended.
In the neoadjuvant setting (treatment before surgery) for higher-risk, HER2-positive breast cancer, pertuzumab is often added to the treatment regimen. Pertuzumab blocks the activation of the HER2 protein.
Regardless of hormone receptor or HER2 status, adjuvant chemotherapy is sometimes necessary for higher-risk tumors, reducing the risk of recurrence for all types of breast cancer. Adjuvant chemotherapy typically involves two or three medications with non-overlapping side effect profiles. Common drugs include cyclophosphamide, methotrexate, doxorubicin, paclitaxel, and docetaxel. Regimens with three chemotherapy medications offer greater benefits but come with increased toxicity.
Side effects and risks of chemotherapy can include fatigue, hair loss, nausea, diarrhea, infection, heart failure, and more. While chemotherapy isn't routinely recommended for certain types of breast cancer, it may be considered based on specific characteristics or gene expression profiling tests like OncotypeDX. Individualized treatment decisions are essential to balance potential benefits and risks.
- Details
- Category: Medical sciences and health
Respiratory symptoms often send folks scrambling to the doctor's office, seeking relief from their woes. When it comes to these symptoms, a whopping seventy percent of patients sporting a persistent cough end up with the diagnosis of acute bronchitis. But that's not all that can make you cough up a storm; pneumonia, cough-variant asthma, a heart that's seen better days (congestive heart failure), postnasal drip, rhinosinusitis, and even accidentally swallowing some of your own saliva can all be culprits.
For those who decide to consult their trusty primary care provider about their cough, here's a little crystal ball action: roughly 10% to 15% of them might be harboring pneumonia. The signs that might point to this not-so-welcome guest include being on the mature side (the odds are 4.6 times higher), feeling breathless (2.4 times more likely), running a fever (5.5 times the chance), having a racing heart (3.8 times more common), and last but not least, the doctor hearing something funky during a chest exam, like crackles (23.8 times the odds) or rhonchi (14.6 times more likely).
As you can see, the world of respiratory infections is quite a mixed bag, with different causes, treatments, and prognoses. Stick around, and we'll unpack it all in this chapter.
The Lowdown on Acute Bronchitis
Acute bronchitis, or AB for short, is a common affliction that tends to strike during the winter season. It's a viral party in your upper respiratory tract, so leave those antibiotics at the pharmacy. The incidence of AB hovers between 30 to 170 cases per 1000 individuals each year. The usual suspects behind this seasonal shindig are rhinoviruses, respiratory syncytial virus, influenza, parainfluenza, and adenovirus. These germs are like party crashers; they spread quickly through respiratory secretions or hitch a ride on shared surfaces.
AB is usually a "get well soon" kind of situation, lasting no more than 1 to 2 weeks. If you find yourself coughing up some gnarly-looking mucus (purulent sputum), don't jump to conclusions—it's more about your respiratory tract doing some spring cleaning than a bacterial invasion.
But, if your symptoms decide to outstay their welcome for over 2 weeks, it's time to play detective. It could be "atypical" bacteria like Bordetella pertussis or Mycoplasma pneumoniae causing trouble, or perhaps another diagnosis entirely, like postnasal drip syndrome, asthma, acid reflux, chronic bronchitis from smoking or other irritants, bronchiectasis, eosinophilic bronchitis, or the use of angiotensin-converting enzyme inhibitors.
Now, let's talk antibiotics. They're not the superhero in this story. Numerous trials and fancy meta-analyses have weighed in, and the verdict is clear: antibiotics don't offer much, if any, benefit in treating AB. In fact, they come with significant costs and potential side effects.
Overprescribing antibiotics for AB contributes to a bigger problem—antimicrobial resistance. In the United States alone, we're talking about over 2 million illnesses and 23,000 deaths related to antibiotic-resistant infections each year, costing more than a whopping $30 billion.
But wait, there's a caveat. Some AB cases do call for treatment, especially during documented B. pertussis (whooping cough) outbreaks or if you have underlying lung issues like chronic obstructive pulmonary disease, asthma, or a smoking habit. In such cases, second-generation macrolides like azithromycin or clarithromycin are the go-to choices.
Community-Acquired Pneumonia: A Persistent Threat
Pneumonia, the "captain of the men of death" as Sir William Osler put it, remains a formidable adversary despite our century-long journey of understanding its inner workings and treatment. It continues to hold its title as the leading infectious cause of death not only in the United States but worldwide.
Over the years, we've witnessed incremental victories in the battle against community-acquired pneumonia (CAP), thanks to medical breakthroughs. These milestones include antipneumococcal serum therapy (unveiled in 1895 and widely embraced by the 1920s), antibiotics (discovered in 1928 and widely used by the 1940s), and mechanical ventilation (revealed in 1952 and adopted in the 1960s). Pneumococcal vaccination, while beneficial, hasn't outshone these prior achievements significantly.
In the United States alone, approximately 4 million CAP cases emerge annually, translating to around 6 cases per 1000 people each year. Among these, 1 million necessitate hospitalization, resulting in 45,000 to 50,000 fatalities. The mortality rate for all hospitalized CAP patients can fluctuate from 2% to a staggering 30%, and those who find themselves in the intensive care unit (ICU) for initial care face an even bleaker prospect, with mortality rates as high as 40%. In stark contrast, outpatients generally fare better, with mortality rates ranging from less than 1% to 3%.
CAP is characterized by an abrupt lung infection, accompanied by a fresh infiltration on a chest X-ray or compatible findings during a lung examination. Typical CAP symptoms often include a mix of these features: fever or abnormally low body temperature, sweating, chills, pleurisy, and a new cough, with or without the production of sputum or changes in the color of respiratory secretions. If your cough isn't producing thick mucus, it might hint at "atypical" culprits like Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella species, or even Bordetella pertussis.
While Streptococcus pneumoniae is still a prevalent cause of CAP, its incidence has dwindled, thanks in part to pneumococcal vaccination. However, "atypical" pathogens are garnering recognition as both outpatient and inpatient CAP instigators, warranting the use of empirical antibiotics in all cases. Yet, identifying the exact cause of CAP often proves elusive in clinical practice. Surprisingly, pathogen identification succeeds in less than 10% of hospital-admitted CAP cases, according to one review of over 17,000 cases. Recent studies utilizing specialized tests like broad-range polymerase chain reaction (PCR) assays have upped the microbiologic diagnosis rate to 38% to 87%, with viruses emerging as the most frequently detected culprits, found in roughly one-third of cases. The high rate of culture-negative CAP can be attributed to various factors, including prior antibiotic use, difficulty in producing suitable sputum samples, viral origins, or as-yet-unidentified emerging pathogens.
To unearth less common pneumonia causes such as Mycobacterium tuberculosis, Coxiella burnetii, and endemic fungi (Coccidioides species, Histoplasma capsulatum, and Blastomyces dermatitidis), epidemiological clues can provide valuable insights.
Diagnosing CAP hinges on the presence of localized pulmonary findings, either through lung auscultation or chest radiography. The latter is crucial for ruling out complications like pleural effusions and potentially hinting at the responsible pathogen (e.g., lymphadenopathy) or alternative diagnoses (e.g., lung mass, lung abscess). However, radiographic patterns don't reliably differentiate specific pathogens, particularly among the elderly and immunocompromised patients who may present unusual or no infiltrates despite having CAP. Post-pneumonia, tobacco smokers and individuals over 65 should undergo follow-up chest radiography within 3 to 6 months to exclude underlying malignancies.
Determining when patients should undergo an extensive microbiologic evaluation for the causative agent remains somewhat tricky. It's typically recommended for immunocompromised patients, those admitted to the hospital or ICU, or those who haven't responded to recent treatment. Hospitalized patients should have at least blood cultures and sputum Gram stain and culture. ICU-bound patients require additional diagnostic testing, including Legionella and pneumococcus urinary antigen tests and multiplex PCR testing, if available. If the etiologic agent remains elusive or the patient's condition deteriorates, individuals with severe pneumonia may undergo bronchoalveolar lavage, which can be sent for bacterial, fungal, mycobacterial, and viral testing.
Several risk-stratification methods have been developed and validated to pinpoint patients with low mortality risk, making home therapy a cost-effective option compared to inpatient stays. The CURB65 risk score is a user-friendly tool based on five simple criteria, including confusion, elevated blood urea nitrogen, rapid respiratory rate, low blood pressure, and age over 65. The higher the CURB65 score, the greater the risk of death or ICU admission.
Another risk assessment method, the pneumonia severity index, takes into account demographic factors (with age playing the biggest role) and key physical and laboratory findings. Notably, aside from arterial oxygenation measurement, all lab tests are at the discretion of the healthcare provider. Patients in risk class I or II can typically receive home care safely, while risk class III patients may still be candidates for home care but warrant close observation. Risk classes IV and V usually require hospital admission. CAP patients with unexplained or severe hypoxemia should be hospitalized, with clinical judgment ultimately outweighing clinical prediction rules.
When it comes to pharmacotherapy principles for CAP, there are a few crucial points to remember: First, once the diagnosis is confirmed, delaying antibiotic administration is associated with higher mortality rates. Second, all CAP patients should receive coverage for "atypical" pathogens. And third, prior antibiotic exposure should influence empirical antibiotic selection. Clinicians should also be on the lookout for specific environmental exposures that might suggest an uncommon pathogen.
A snapshot of the Infectious Diseases Society of America (IDSA) and American Thoracic Society combined recommendations is provided for easy reference. Once the responsible organism is identified, antibiotics should be adjusted to target that specific pathogen with minimal spectrum overlap and cost. Treatment typically lasts 5 to 7 days, though some pathogens like Staphylococcus aureus, Legionella species, and Pseudomonas aeruginosa may require a longer duration. The IDSA guidelines advocate transitioning patients from intravenous to oral therapy when they're clinically improving, hemodynamically stable, and able to take oral medications. Antibiotics can be discontinued once patients have maintained clinical stability for 48 hours, defined by normal body temperature, heart rate, respiratory rate, blood pressure, and oxygen saturation on room air. Unlike clinical improvement, chest radiography doesn't dictate treatment duration as pneumonia resolution often lags behind clinical recovery.
For most patients, pneumonia symptoms start improving within 3 to 5 days of initiating treatment. When pneumonia doesn't resolve, it could be due to factors like an atypical pathogen not covered by standard therapy (e.g., Mycobacterium tuberculosis, Coccidioidomycosis), antibiotic-resistant organisms, loculated infections like empyema, underlying malignancies, or noninfect